Guggenheim analyst Subbu Nambi raised the firm’s price target on Personalis (PSNL) to $12 from $6 and keeps a Buy rating on the shares after the company announced Medicare coverage for NeXT Personal in breast cancer. This first covered indication keeps Personalis on track for their goal of two indications by year end, notes the analyst, who views this as “a major win for the story” that derisks the clinical revenue outlook for 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis price target raised to $13 from $10 at H.C. Wainwright
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- Personalis Secures Medicare Coverage for NeXT Personal MRD Test, Positioning for Growth in Underpenetrated $20 Billion Market
- Personalis Gains Medicare Coverage for Cancer Test
- Personalis announces Medicare coverage of NeXT Personal test